Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here we go again...I wouldnt call a 10 percent day on VERY low volume a bad day at all.
absolutely not a safe play at all, but I do believe in the company.
You call this a pump?
Here are results from the 771 patient trial in 2006 with genasense...now compare this to the most recent agenda update and tell me whos not paying attention idiot. Read the bold print, simply the data is just not mature yet, and if you look at older information you can see that that genasense showed MUCH better results for the long term picture.
Results: Among 771 patients randomly assigned, the addition of oblimersen to dacarbazine yielded a trend toward <bold>improved survival at 24-month minimum follow-up </bold> (median, 9.0 v 7.8 months; P = .077) and significant increases in progression-free survival (median, 2.6 v 1.6 months; P < .001), overall response (13.5% v 7.5%; P = .007), complete response (2.8% v 0.8%), and durable response (7.3% v 3.6%; P = .03). A significant interaction between baseline serum LDH and treatment was observed; oblimersen significantly increased survival in patients whose baseline serum LDH was not elevated (median overall survival, 11.4 v 9.7 months; P = .02). Neutropenia and thrombocytopenia were increased in the oblimersen-dacarbazine group; however, there was no increase in serious infections or bleeding events.
Conclusion: The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.
now compare that to our recent press release.
AGENDA did not show a statistically significant benefit for its co-primary endpoint of progression-free survival. Secondary endpoints of overall response rate and disease control rate (which includes complete and partial responses, plus stable disease ≥ 3 months duration) also did not show a statistically significant benefit. According to the prespecified analysis plan, the statistical significance of durable response – a secondary endpoint that measures the proportion of patients who achieved a complete or partial response that lasts ≥ 6 months – is too early to evaluate. The observed differences in progression-free survival, overall response, disease control and durable response all numerically favored the group that received Genasense®.
Overall survival – the other co-primary endpoint in AGENDA – is too early to evaluate, as prospectively specified. An analysis for futility, which was defined as ≥ 50% conditional power to observe a statistically significant benefit of Genasense under the prospectively assumed hazard ratio of 0.69, has been conducted for the co-primary endpoint of overall survival. AGENDA has passed this futility analysis. The prospectively specified analyses for both overall survival and durable response will be conducted when the data are mature. The safety profile of Genasense in AGENDA was consistent with prior studies.
That is the latest version of the company presentation. It is old but it still tell what is in store for this year, and it is all suppose to happen before "funding runs out"
Ive been invested in this company for well over a year, by no means am I a pumper or a "cyber pocket picker" I am a realist yes this is a risky investment, but at this point in the game the company is undervalued. If this is so risky why are you wasting your time telling people not to invest? Please my friend know before you go.
You guys are crazy. Why are people holding? This is why!
http://genta.com/docs/Website%20Corporate_Presentation_03-10-09.pdf go down to slides 45 and 46...
AS Stated
Genasense Phase 3 melanoma: accrual completes Q1 09
Tesetaxel: Orphan drug designations Q1 09
Tesetaxel results from ongoing U.S. trial H1 09
Genasense EU: “cohort ATU” H2 09
Melanoma AGENDA data: final PFS H2 09
Tesetaxel gastric cancer trial: SPA completed H2 09
Melanoma NDA/MAA H2 09
Genasense is a major commercial opportunity
• Regulatory approvals asap:
• Confirmatory Phase 3: melanoma
• Establish improved dosing schedule
• Named-patient program ensures access
• Pipeline clinical introductions accelerate
• Ongoing partnering activities
I beg to differ, did you vote?
http://genta.com/docs/Genta%20proxy%20filed%20with%20SEC%2021JULY2009.pdf
Nutriman, out of curiousity and for some DD purposes can you give the the link to that website that we though was going to be released to the public when you get a chance
From what I have read they had enough cash to finish agenda correct? That was released back in August when financing was secured. As for the drop you are thinking we will see on Nov 17th I think you are wrong, if there is going to be a drop it will be Nov 16th at 9:30 am after the conference call. They are going over financials and cost cutting techniques which means if they are going to let a cat out of the bag, that is the time to do it. As for the presentation the company wants to be as marketable as possible which means they are not going to setup a booth and present failure/bad outlook to the public. If you were the CEO of Genta and you were strapped for Cash would you present your pipeline in a negative fashion to the public? I would hope not, you would want to make yourself as marketable as possible, giving hope for future funding and or a buy out.
***AGENDA Trial Currently Remains Active to Enable Potential Evaluation for Overall Survival***
He has funding to complete agenda, whether it be january of 2010 or january of 2011 agenda will be fully funded and completed before the the bank is empty.
You make absolutely no sense. What this PR says is they are not giving up on agenda, and we already know financing HAS ALREADY BEEN SECURED to complete agenda. What is it with you guys on here no disrespect but you all have a habbit of putting your foot in your mouth. We know agenda is fully funded why would they dillute now, sure if they said their priority was now CLL/Tesataxel and agenda was done than we would have to worry, but this has already been settled.
I think we all need to take a step back to 2006 when we conducted the largest trial ever that related to advanced melanoma. The endpoints were different the reason this was not approved after these results is because the FDA wanted more data.
BERKELEY HEIGHTS, NJ – September 15, 2006 – Genta Incorporated (NASDAQ:
GNTA) announced that results of the Company’s Phase 3 trial of Genasense® (oblimersen
sodium) Injection in patients with advanced melanoma were published on-line this week in
the Journal of Clinical Oncology, ahead of its print publication date of October 10, 2006.
The paper is accompanied by an editorial that discusses the trial’s results in the context of
current options for melanoma treatment. The extended follow-up data from this
publication form the basis of a Marketing Authorization Application (MAA) that is
currently pending review by the European Medicines Agency (EMEA).
“In our paper, long-term followup has confirmed the trends that were observed in the
earlier analyses”, said Dr. Agop Y. Bedikian, Professor of Medicine at M.D. Anderson
Cancer Center, Houston, TX, who is the lead author on the paper. “This was the first trial
to achieve such a broad array of positive endpoints. I believe the aggregate data indicate
that Genasense can be a major addition to chemotherapy for patients with this disease, with
a side-effect profile that is highly manageable.” The article can be accessed on-line at:
http://www.jco.org/cgi/content/abstract/JCO.2006.06.0483v1.
Genasense, Genta’s lead anticancer drug, is a novel targeted therapy that blocks the
production of Bcl-2, a protein that appears to be a fundamental cause of resistance to
cancer treatment. By knocking down Bcl-2 in cancer cells, Genasense may enhance the
effectiveness of chemotherapy in patients with advanced melanoma. A summary of the
data from the final analysis appears below.
Efficacy Data
The report is based on long-term data derived from the largest randomized controlled trial
that has ever been conducted in patients with advanced melanoma. In this trial, which was
conducted at 139 sites in 9 countries, 771 patients were randomly assigned to receive
chemotherapy with dacarbazine (DTIC) alone or in combination with Genasense. The
paper includes data from a prospectively defined analysis that evaluated 24-months of
minimum follow-up on all patients. Unless otherwise noted, these results were based on
an intent-to-treat analysis:
Endpoint Genasense/DTIC DTIC P
Overall response 13.5% 7.5% 0.007
Complete response 2.8% 0.8% 0.03
Durable response 7.3% 3.6% 0.03
Progression-free survival, median 2.6 mos. 1.6 mos. 0.0007
Overall survival, median 9.0 mos. 7.8 mos. 0.077
Prior to randomization, patients were prospectively stratified according to certain risk
factors, including elevated blood levels of an enzyme known as LDH – a factor that
previous clinical studies have shown is strongly associated with poor outcome. The final
analysis has shown that LDH was the sole stratification factor significantly associated with
a treatment interaction. When this treatment effect was evaluated, the efficacy of
Genasense was significantly superior for all major efficacy outcomes in patients who had
normal LDH at baseline, a group that comprised approximately two-thirds of patients in
the trial (N=508). In this group, the following efficacy results were observed:
Endpoint Genasense/DTIC DTIC P
Overall response 17.2% 9.3% 0.009
Complete response 3.4% 0.8% 0.04
Durable response 9.6% 4.0% 0.014
Progression-free survival, median 3.1 mos. 1.6 mos. 0.0007
Overall survival, median 11.4 mos. 9.7 mos. 0.018
Safety Data
The most frequent serious adverse events that occurred in ≥ 5% of patients were fever and
disease progression (6.2% vs. 2.8%, and 5.1% vs. 4.7%, respectively, for Genasense/DTIC
compared with DTIC alone). The most frequent Grade 3 or 4 adverse events that occurred
in ≥ 5% of patients were neutropenia (21.3% vs. 12.5%), thrombocytopenia (15.9% vs.
6.4%), leukopenia (7.5% vs. 3.9%), anemia (7.3% vs. 4.7%), and nausea (6.7% vs. 2.5%).
Although there was an increase in discontinuations due to adverse events in the Genasense
arm (19% vs. 11%), there was no difference in the number of fatal, treatment-emergent
adverse events
I am a network engineer myself and from what I was able to see the new and old website were on the same subnet but I dont know much about the provider, it could have been spoofed easily. If I was able to see the new website myself and where it was hosted I would believe it a bit more but apparently when I heard the news the site was already down...
A) It's real and they caught on
B) Someones a paid pumper with some networking skills who simply made it look like it was on the same server when he took the screenshot
C)It was a spoof and whoever did it just happened to sign up with the same webhost to make it more believeable
The only reason I dont see this happening is because its not like it was just one page, it was multiple pages that were created. Now if this was fake...I sure hope that person has insurance because they are liable and could have their asses handed to them in a court case for something like that.
If it is fake whoever created it or should I say discovered should be careful, fraud and the stock market is nothing to mess around with.
Get ready for Monday, strong close.
I am sure whoever invested the money for them (rodman i believe) to survive through Agenda did their homework before they handed out millions of dollars to a company whos only direction has been down. This happens A LOT of wallstreet smit, price is intentionally driven down and it gives people a chance to steal/buy low. Trust me, as mentioned earlier there is always a plan B. As far as I am concerned Plan A is not out of the picture.
Not to mention the financing came after the share conversion...do you really think they want to sell their shares for this much of a loss? I honeslty do not see this being dilluted, their low float makes it easier to acquire now if they need to sell out.
They had no money to get through, they had enough money to get them through "agenda" which means they will find money to get them through the next step...even if Agenda was succesful they would still need to find a way to find funds to deliver the product.
Common sense. Company has 5 other drugs, 1 on the market and yet 80 percent of the companies value disapeared yesterday, I will let you do the math. It is way oversold
watcho out with that stock... I lost my a$$ in INAR about 3 months ago...was playing a breakout and it pulled back hard.
lol buddy, I was here on this board long before you, Ive had this stock for over a year, and I know a lot more about this company than you my friend, don't believe me go on over to HSM and read my post history on GNTA. Fear is what makes money on the market, and you my friend demonstrated fear while I profited off of it.
PS look at the B/A spread tighten now...here is your next leg up.
Trust me Id be the first one to sell yesterday if I didnt think there was any hope in this company, they are not running out of funding tomorrow guys. They extended their lease yet again, they have promised future payments to their landlord in 2011, they have about 5 other drugs including 1 on the market, and as of rightnow the float is extremely low. WAY too much could happen in the short term...for all we know this could be a buck by next week.
Not to mention this thing is trading like a bull right now...so much for the sell off...leg up to 23..pull back to 21 ...leg up to 24...pull back to 22 ...leg up to 27..pull back to 24
No guts no glory, I am not pumping by any means but this thing is way oversold.
You two keep agreeing with each other whats up with that? Be realistic here guys, sure they dont have any money and maybe genasense will be a complete failure for THEM. But...keep in mind it still has *potential* and they do have other drugs in their pipeline. They said they are in the process of finding partners...perhaps that is what that website is all about...a new look..a new way. Either way Im holding this as a write off but I think this is way oversold, and undervalued. The float is low now and with other products in their portfolio the speculation of a partnership in the future is only going to cause a rise in the stock price.
just listened to it...what I posted is completely different from the Agenda trial and results are expected in 4th quarter as well. Also there are MANY ongoing discussions of partnerships but NONE with Genasense. This leaves me to believe A)It is their bread and butter and they dont want to give it up B) They knew it was not worth anything, and it would fail. Scenario B makes teh most sense...and given that information why would Ray turn around and purchase 26 million shares?
link does not work
is there a recording from today?
ON August 14th...BTW this does not Say AGENDA
"The last several months have been extraordinarily important", said Dr. Raymond P. Warrell, Jr., Genta's Chief Executive Officer. "We now believe we will have sufficient financing that will enable release of primary data in our Phase 3 Genasense® trial in melanoma. Certainly, past and recent studies of other drugs in melanoma have proved repeatedly disappointing. We believe our biomarker-directed approach, coupled with our uniquely targeted new drug, may transform the treatment of this illness and finally offer meaningful benefit for patients. We expect to release results from our Phase 3 study within the next 3 months, which if positive should comprise the basis for worldwide regulatory applications."
The Company's landlord received a termination payment of $1.3 million, comprised of security deposits, and will receive a future payment of $2.0 million on January 1, 2011.
I faced reality, bought more this morning, you have NO idea what their market is worth.
PPS has nothing to do with this, don't go posting non sense if you have no idea what you are talking about. How do you know what the tesataxel market is worth? What makes you think 20+ years worth of research is worth pennies? Not only do they have a huge pipleline of drugs, but they also have ganite...which is on the market.
based *ON* Melanoma...DUDE.
Tell me...when cars go through crash test ratings do you think they just drive it into a 5 ton mac truck and if everyone dies it fails? No. Testing needs to be looked at from all angles. Go back and read some more news...it is known that this drug works best when used with chemo.
2nd Quarter Report 2009 dated August 14 that Median survival was 14.7 months and 50% of patients had survived longer than 1 year
These data compared favorably with median survival reported in the prior Phase 3 trial of Genasense in melanoma with similar LDH criteria for dacarbazine alone (9.7 months) or dacarbazine plus Genasense (11.4 months).
Trial III of AGENDA: Genasense + Dacarbazine
Method: Non-Chemotherapy
results - failed
Trial III of Genasense + Temozolomide + Abraxane
Method: Chemotherapy
Release result: in the Fourth Quarter of 2009
Interim results: Median survival was 14.7 months and 50% of patients had survived longer than 1 year
These data compared favorably with median survival reported in the prior Phase 3 trial of Genasense in melanoma with similar LDH criteria for dacarbazine alone (9.7 months) or dacarbazine plus Genasense (11.4 months).
http://www.genta.com/investor%20relation...
DO SOME RESEARCH DUDE!
The agenda Trial is not based around melanoma, don't forget about CLL, NHL, Tesataxel, Ganite...and whatever that other drug is. Now...when you ask the question...do you want to the good news or the bad news first...what do 90 percent of the people respond with? Give me the bad and get it over with....come on...why not drive the price down intentionally..suck up some shares...and make even more money. If you guys knew anything about this company you would have already known melanoma results are a long shot...I think the sell of was a bunch of people who had no knowledge of the company what so ever other than the word agenda. THis is part of the agenda yes...but a very very VERY small portion of it.
http://www.drugs.com/nda/genasense_070404.html
Let me take you guys back in history just so I know you understand what genasense is...the results using Genasense with CLL have been beyond fantastic and the company knows it. Just to give you guys a true lesson in history...this is what we are waiting on.
http://www.drugs.com/nda/genasense_070404.html
I love how 90 percent of this board calls themselves longs, if you are a long you obviously would not be selling right now. Honestly, anyone selling at these levels is a complete moron. Have you guys done any DD what so ever? Everyone knows genasense was not very effective in melanoma that was just iceing on the cake. Go back about 6 months and read the response from the FDA, and than make sure you know what agenda is as well.
1) Know the market - Buy low Sell high
2) Average down
3) Know the company
4) Statistics were provided on a ***3 MONTH*** basis, which means...they know this 3 months after the Agenda started hmmm...Remember when agenda started? It was more than 3 months before the board bought a boatload of shares.
5) Melanoma is 1/3 of the Agenda trial people, and 1/5 of the companies value, so why wouldnt the stock drop 20 percent instead of 80? People dont know what they are doing. You have a company that is definitly worth something and you can bet your ass no ones going to let it go to waste. I'll take bets from anyone that this company is bought out or in the process of big things with out keeping them public.
6) DO you really think that website was BS? Tell me if you owned a business and you knew you had hit the bottom would you take money of your small pocket and pay someone to do a website for your business you knew was going under? Come on people be realistic, if you sold, you got screwed.
It would have had to of been posted on the insider transaction list when it was sold...he is holding.
Guys I dont know if I would freak out just yet...it may be a reach but has anyone looked at the insider transaction list?
31-Aug-09 SIEGEL GARY
Officer 2,941,631 Direct Acquisition (Non Open Market) N/A
31-Aug-09 SANDERS WALTER LLOYD
Officer 4,412,446 Direct Acquisition (Non Open Market) N/A
31-Aug-09 ITRI LORETTTA M
Officer 9,071,990 Direct Acquisition (Non Open Market) N/A
31-Aug-09 WARRELL RAYMOND P JR
Officer 26,474,679 Direct Acquisition (Non Open Market) N/A
26-Aug-09 PARIOS CHRISTOPHER P
Director 695,658 Direct Acquisition (Non Open Market) N/A
26-Aug-09 WATSON DOUGLAS G
Director 695,658 Direct Acquisition (Non Open Market) N/A
26-Aug-09 VON HOFF DANIEL
Director 695,658 Direct Acquisition (Non Open Market)
These Agenda results were in before all of these aquisitons now tell me...if you were Ray...would you by 26 million shares of a company that had a drug that would fail?
If we recently had news released and we were seeing this I would be a little concerned but there is just a whole lot of panic selling going on. We are nearing the holidays and the tax season is not that far off....you will see a lot of profit takers in the coming months but I don't think we have too much to worry about here. I do firmly believe we should hear something shortly...my advice to anyone in here is average down when you can.
I think everyone needs to take a reality check here, yes every once and a while a penny stock may go from bottom of the barrel to the top of the top but what you are seeing is normal, smart, trading. I believe in neomedia a lot but as we all know there are a lot of underlying issues. My advice to everyone here is play it safe. It is not always about going for the home run swing, base hits and solid defense wins ball games.You have not made a dime on the market until you sell the stock.
Chart does not look all that great